New Alternative Found for Boosting Ovarian Cancer Immune Responses

New Alternative Found for Boosting Ovarian Cancer Immune Responses
Researchers at The Wistar Institute in Philadelphia have identified an experimental drug that shows great promise in halting ovarian cancer progression. The treatment, which is currently in clinical trials for a number of cancers, is able to boost anti-tumor immunity and cause T-cells to directly target ovarian cancer cells. The study, “BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression,” is published in the journal Cell Reports. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Few effective treatments have been approved to treat this deadly cancer. Tumors evade anti-tumor immunity through inhibitory pathways that regulate the function of T lymphocytes, known as immune checkpoints. The programmed cell death (PD)-1 protein is predominantly expressed on the surface of T-cells, while its ligands, such as PD-L1, are expressed on the surface of both immune and ovarian cancer cells. The interaction between
Subscribe or to access all post and page content.